Ontvang nu dagelijks onze kooptips!
word abonnee
sluiten ✕
Terug naar discussie overzicht
Kan de EMEA nog om Rhucin heen?
Volgen
European Medicines Agency 7 Westferry Circus, Canary Wharf, London, E14 4HB, UK Tel. (44-20) 74 18 84 00 Fax (44-20) 74 18 86 68 E-mail: mail@emea.europa.eu www.emea.europa.eu ©EMEA 2007 Reproduction and/or distribution of this document is authorised for non commercial purposes only provided the EMEA is acknowledged London, 13 December 2007 Doc. Ref. EMEA/567761/2007 QUESTIONS AND ANSWERS ON RECOMMENDATION FOR THE REFUSAL OF THE MARKETING AUTHORISATION for RHUCIN International non-proprietary name (INN): recombinant human C1 inhibitor On 13 December 2007, the Committee for Medicinal Products for Human Use (CHMP) adopted a negative opinion, recommending the refusal of the marketing authorisation for the medicinal product Rhucin 150 U/ml powder for solution for injection, intended for the treatment of acute attacks of angioedema in patients with congenital C1 inhibitor activity deficiency. The company that applied for authorisation is Pharming Group N.V. It may request a re-examination of the opinion within 15 days of receipt of notification of this negative opinion. What is Rhucin? Rhucin is a powder to be made up into a solution for injection into a vein. It contains the active substance recombinant human C1 inhibitor. What was Rhucin expected to be used for? Rhucin was expected to be used to treat sudden attacks of angioedema (swelling of the blood vessels). It was to be used in patients who have low levels of a protein called ‘C1 inhibitor’ due to a congenital (inborn) deficiency. Rhucin was designated as an orphan medicinal product on 11 May 2001 for treatment of angioedema caused by C1 inhibitor deficiency. How is Rhucin expected to work? The active substance in Rhucin, recombinant C1 inhibitor, is very similar to the natural blood protein ‘C1 inhibitor’. C1 inhibitor is normally found in the blood, where it dampens down the activity of the ‘complement system’, which is part of the immune system (the body’s natural defences). Patients with low levels of the active form of C1 inhibitor suffer from attacks of inflammation and swelling that affect various sites in the body. Rhucin was expected to be used as a replacement for the missing C1 inhibitor, correcting the deficiency and reducing the inflammation and swelling that cause angioedema. The active substance in Rhucin is produced using ‘recombinant DNA technology’: it is extracted from the milk of rabbits that have had a gene (DNA) inserted, which makes them able to produce the human protein in their milk. What documentation did the company present to support its application to the CHMP? The effects of Rhucin were first tested in experimental models before being studied in humans. Rhucin was studied in two main studies involving a total of 48 adults with C1 inhibitor deficiency. In both studies, patients were given Rhucin if they had an attack of angioedema. In total, 17 attacks were treated in a total of 12 patients, but both studies were still ongoing at the time of the medicine’s initial assessment. The main measure of effectiveness was how long it took for the patient’s symptoms to improve. During the evaluation procedure, the company also supplied the initial results of a study comparing the effects of Rhucin with those of placebo (a dummy treatment). This included results from 25 patients. The CHMP also took safety data from studies on healthy volunteers and patients without symptoms who were treated with Rhucin into account. Het was in December 2007 en de daar op volgende her aanvraag op een paar belangrijke maar nu achterhaalde puntjes na bijna al gelukt! Die goedkeuring daar zal men het ook bij de EMEA over eens zijn kan en moet men nu niet omheen willen. Als er zoals Pharming melde No major concerns zijn dan zal het beoordelen van de gegeven antwoorden ook een fluitje van een cent zijn. Dus houden we de April meeting goed in de gaten.:-) Ruud..
Ik denk niet de EMEA zich onder druk laat zetten door dit forum e/o haar leden. En dat is maar goed ook. MvG, Philos.
Filasoft schreef:
Ik denk niet de EMEA zich onder druk laat zetten door dit forum e/o haar leden. En dat is maar goed ook.
MvG,
Philos.
het is alleen maar te hopen, dat de EMEA niet plat is en omgekocht door andere Pharmaci- partijen, die niet willen dat Pharming op de martk komt, duimen maar .............
Fabelr schreef:
[quote=Filasoft]
Ik denk niet de EMEA zich onder druk laat zetten door dit forum e/o haar leden. En dat is maar goed ook.
MvG,
Philos.
[/quote]
het is alleen maar te hopen, dat de EMEA niet plat is en omgekocht door andere Pharmaci- partijen, die niet willen dat Pharming op de martk komt, duimen maar .............
ab
ingrid030 schreef:
[quote=Fabelr]
[quote=Filasoft]
Ik denk niet de EMEA zich onder druk laat zetten door dit forum e/o haar leden. En dat is maar goed ook.
MvG,
Philos.
[/quote]
het is alleen maar te hopen, dat de EMEA niet plat is en omgekocht door andere Pharmaci- partijen, die niet willen dat Pharming op de martk komt, duimen maar .............
[/quote]
ab
laat ons duimen en bidden tot de Heer, dat alles goed gaat komen met Pharming.... Amen ..
First report on the Agency's Benefit-Risk Methodology Project published Published 22/04/2010 A summary report on the first work package of the European Medicines Agency's Benefit-Risk Methodology Project – a project aiming to increase the consistency and transparency of the regulatory process through standardised practices for assessing the benefit-risk balance of medicines – has been published. "Introduction During the March 2008 plenary meeting, the Committee for Human Medicinal Products (CHMP) adopted the Reflection paper on benefit-risk assessment methods in the context of the evaluation of marketing authorisation applications of medicinal products for human use (EMEA/CHMP/15404/2007). One of the main recommendations for the CHMP was to explore further methodologies for benefit-risk analysis, including a wide range of quantitative and semi-quantitative tools, and involving assessors and experts. A consequence of this was the initiation of the Benefit-Risk Methodology Project in which the five National Competent Authorities of France, The Netherlands, Spain, Sweden and UK volunteered to participate. A project team was formed involving experts in the field of decision theory. The main objective of this project is to further explore methodologies that can improve the current practice of benefit-risk assessment for medicinal products, with an aim to increase the consistency and transparency of the regulatory process." ................ "Results Between June and September 2009, the project team was invited to visit the five participating agencies (France, The Netherlands, Spain, Sweden and UK). At a later point, Paul-Ehrlich-Institut volunteered to participate in the project and was included in the visits in February 2010. In total, 55 people, involved in the benefit-risk decision making, were interviewed within the six agencies. At present, there are no common definitions on the concepts of benefits and risks and no formal guidance on the process of their balancing. As a result, interviewees, between agencies and within the same agency, expressed divergent views on the meaning of benefits and risks, and on their weighing. Especially with regard to risks, there was a great variance of responses. Most notably, the uncertainty of realising a benefit from the use of a pharmaceutical product was frequently mentioned as a risk. In practice, formulating a benefit-risk balance for a medicinal product is an intuitive and implicit process based on expert judgement. In all the six agencies there was no mention of the use of a validated and structured process for assessing benefits and risks. In contrast, most of the interviewees acknowledged the need for a more systematic approach and the value it can add. A few assessors mentioned the use of a self-constructed and simplistic method for balancing benefits and risks. The benefit-risk balance is generally considered as the most difficult part of the assessment process, even for experienced assessors. It was mentioned that the most challenging situations are those in which there is substantial uncertainty about the benefits and the risks of a product, the products belong to a new class of drugs, or the products belong to the therapeutic area of oncology."www.ema.europa.eu/pdfs/human/brmethod...
Ahh Declan, wat moet je hier nu op zeggen. Ik zou je graag gelijk willen geven, maar de uitslag is in handen van de hogere geleerden die niet alleen de werking en de effictiviteit van ruchin moeten bekijken aan de hand van de clinicaltrails en hun uitkomsten. Anderzijds is de puurheid goed genoeg om inschatting te kunnen maken dat het echt safe is zonder nieuwe generaties ziekte te genereren. Juiste balance tussen winst en risico, waarin het bijwerkingseffect heel veel zwaarte heeft. Wanneer men ook maar twijfelt aan mogelijke bijwerkingen is het klaar. Dat was de 1e,2e keer van belang en nu dus weer. Moet niet vergeten dat het gewonnen wordt uit een dierenproduct en dus zeker nu we erg veel last hebben van bijv QKoorts,Vogelgriep etc. Moet er niet aan denken dat we daar ook nog VHS en Myxomatose aan toe kunnen voegen Arak
FDAnews Drug Daily Bulletin April 22, 2010 | Vol. 7 No. 79 Experts: More Transparency Needed in EMA New Drug Approval Process The European Medicines Agency (EMA) should increase the transparency of its drug approval process by releasing substantial parts of drug dossiers to the scientific community. Greater transparency would “help independent interested parties define the benefit-risk profile of new medicines before they are allowed onto the market,” according to Silvio Garattini, director of the Mario Negri Institute for Pharmacological Research in Milan, and Vittorio Bertele, head of the institute’s drug regulatory policies laboratory.
Aantal posts per pagina:
20
50
100
Direct naar Forum
-- Selecteer een forum --
Koffiekamer
Belastingzaken
Beleggingsfondsen
Beursspel
BioPharma
Daytraders
Garantieproducten
Opties
Technische Analyse
Technische Analyse Software
Vastgoed
Warrants
10 van Tak
4Energy Invest
Aalberts
AB InBev
Abionyx Pharma
Ablynx
ABN AMRO
ABO-Group
Acacia Pharma
Accell Group
Accentis
Accsys Technologies
ACCSYS TECHNOLOGIES PLC
Ackermans & van Haaren
ADMA Biologics
Adomos
AdUX
Adyen
Aedifica
Aegon
AFC Ajax
Affimed NV
ageas
Agfa-Gevaert
Ahold
Air France - KLM
Airspray
Akka Technologies
AkzoNobel
Alfen
Allfunds Group
Allfunds Group
Almunda Professionals (vh Novisource)
Alpha Pro Tech
Alphabet Inc.
Altice
Alumexx ((Voorheen Phelix (voorheen Inverko))
AM
Amarin Corporation
Amerikaanse aandelen
AMG
AMS
Amsterdam Commodities
AMT Holding
Anavex Life Sciences Corp
Antonov
Aperam
Apollo Alternative Assets
Apple
Arcadis
Arcelor Mittal
Archos
Arcona Property Fund
arGEN-X
Aroundtown SA
Arrowhead Research
Ascencio
ASIT biotech
ASMI
ASML
ASR Nederland
ATAI Life Sciences
Atenor Group
Athlon Group
Atrium European Real Estate
Auplata
Avantium
Axsome Therapeutics
Azelis Group
Azerion
B&S Group
Baan
Ballast Nedam
BALTA GROUP N.V.
BAM Groep
Banco de Sabadell
Banimmo A
Barco
Barrick Gold
BASF SE
Basic-Fit
Basilix
Batenburg Beheer
BE Semiconductor
Beaulieulaan
Befimmo
Bekaert
Belgische aandelen
Beluga
Beter Bed
Bever
Binck
Biocartis
Biophytis
Biosynex
Biotalys
Bitcoin en andere cryptocurrencies
bluebird bio
Blydenstijn-Willink
BMW
BNP Paribas S.A.
Boeing Company
Bols (Lucas Bols N.V.)
Bone Therapeutics
Borr Drilling
Boskalis
BP PLC
bpost
Brand Funding
Brederode
Brill
Bristol-Myers Squibb
Brunel
C/Tac
Campine
Canadese aandelen
Care Property Invest
Carmila
Carrefour
Cate, ten
CECONOMY
Celyad
CFD's
CFE
CGG
Chinese aandelen
Cibox Interactive
Citygroup
Claranova
CM.com
Co.Br.Ha.
Coca-Cola European Partners
Cofinimmo
Cognosec
Colruyt
Commerzbank
Compagnie des Alpes
Compagnie du Bois Sauvage
Connect Group
Continental AG
Corbion
Core Labs
Corporate Express
Corus
Crescent (voorheen Option)
Crown van Gelder
Crucell
CTP
Curetis
CV-meter
Cyber Security 1 AB
Cybergun
D'Ieteren
D.E Master Blenders 1753
Deceuninck
Delta Lloyd
DEME
Deutsche Cannabis
DEUTSCHE POST AG
Dexia
DGB Group
DIA
Diegem Kennedy
Distri-Land Certificate
DNC
Dockwise
DPA Flex Group
Draka Holding
DSC2
DSM
Duitse aandelen
Dutch Star Companies ONE
Duurzaam Beleggen
DVRG
Ease2pay
Ebusco
Eckert-Ziegler
Econocom Group
Econosto
Edelmetalen
Ekopak
Elastic N.V.
Elia
Endemol
Energie
Energiekontor
Engie
Envipco
Erasmus Beursspel
Eriks
Esperite (voorheen Cryo Save)
EUR/USD
Eurobio
Eurocastle
Eurocommercial Properties
Euronav
Euronext
Euronext
Euronext.liffe Optiecompetitie
Europcar Mobility Group
Europlasma
EVC
EVS Broadcast Equipment
Exact
Exmar
Exor
Facebook
Fagron
Fastned
Fingerprint Cards AB
First Solar Inc
FlatexDeGiro
Floridienne
Flow Traders
Fluxys Belgium D
FNG (voorheen DICO International)
Fondsmanager Gezocht
ForFarmers
Fountain
Frans Maas
Franse aandelen
FuelCell Energy
Fugro
Futures
FX, Forex, foreign exchange market, valutamarkt
Galapagos
Gamma
Gaussin
GBL
Gemalto
General Electric
Genfit
Genmab
GeoJunxion
Getronics
Gilead Sciences
Gimv
Global Graphics
Goud
GrandVision
Great Panther Mining
Greenyard
Grolsch
Grondstoffen
Grontmij
Guru
Hagemeyer
HAL
Hamon Groep
Hedge funds: Haaien of helden?
Heijmans
Heineken
Hello Fresh
HES Beheer
Hitt
Holland Colours
Homburg Invest
Home Invest Belgium
Hoop Effektenbank, v.d.
Hunter Douglas
Hydratec Industries (v/h Nyloplast)
HyGear (NPEX effectenbeurs)
HYLORIS
Hypotheken
IBA
ICT Automatisering
Iep Invest (voorheen Punch International)
Ierse aandelen
IEX Group
IEX.nl Sparen
IMCD
Immo Moury
Immobel
Imtech
ING Groep
Innoconcepts
InPost
Insmed Incorporated (INSM)
IntegraGen
Intel
Intertrust
Intervest Offices & Warehouses
Intrasense
InVivo Therapeutics Holdings Corp (NVIV)
Isotis
JDE PEET'S
Jensen-Group
Jetix Europe
Johnson & Johnson
Just Eat Takeaway
Kardan
Kas Bank
KBC Ancora
KBC Groep
Kendrion
Keyware Technologies
Kiadis Pharma
Kinepolis Group
KKO International
Klépierre
KPN
KPNQwest
KUKA AG
La Jolla Pharmaceutical
Lavide Holding (voorheen Qurius)
LBC
LBI International
Leasinvest
Logica
Lotus Bakeries
Macintosh Retail Group
Majorel
Marel
Mastrad
Materialise NV
McGregor
MDxHealth
Mediq
Melexis
Merus Labs International
Merus NV
Microsoft
Miko
Mithra Pharmaceuticals
Montea
Moolen, van der
Mopoli
Morefield Group
Mota-Engil Africa
MotorK
Moury Construct
MTY Holdings (voorheen Alanheri)
Nationale Bank van België
Nationale Nederlanden
NBZ
Nedap
Nedfield
Nedschroef
Nedsense Enterpr
Nel ASA
Neoen SA
Neopost
Neovacs
NEPI Rockcastle
Netflix
New Sources Energy
Neways Electronics
NewTree
NexTech AR Solutions
NIBC
Nieuwe Steen Investments
Nintendo
Nokia
Nokia OYJ
Nokia Oyj
Novacyt
NOVO-NORDISK AS
NPEX
NR21
Numico
Nutreco
Nvidia
NWE Nederlandse AM Hypotheek Bank
NX Filtration
NXP Semiconductors NV
Nyrstar
Nyxoah
Océ
OCI
Octoplus
Oil States International
Onconova Therapeutics
Ontex
Onward Medical
Onxeo SA
OpenTV
OpGen
Opinies - Tilburg Trading Club
Opportunty Investment Management
Orange Belgium
Oranjewoud
Ordina Beheer
Oud ForFarmers
Oxurion (vh ThromboGenics)
P&O Nedlloyd
PAVmed
Payton Planar Magnetics
Perpetuals, Steepeners
Pershing Square Holdings Ltd
Personalized Nursing Services
Pfizer
Pharco
Pharming
Pharnext
Philips
Picanol
Pieris Pharmaceuticals
Plug Power
Politiek
Porceleyne Fles
Portugese aandelen
PostNL
Priority Telecom
Prologis Euro Prop
ProQR Therapeutics
PROSIEBENSAT.1 MEDIA SE
Prosus
Proximus
Qrf
Qualcomm
Quest For Growth
Rabobank Certificaat
Randstad
Range Beleggen
Recticel
Reed Elsevier
Reesink
Refresco Gerber
Reibel
Relief therapeutics
Renewi
Rente en valuta
Resilux
Retail Estates
RoodMicrotec
Roularta Media
Royal Bank Of Scotland
Royal Dutch Shell
RTL Group
RTL Group
S&P 500
Samas Groep
Sapec
SBM Offshore
Scandinavische (Noorse, Zweedse, Deense, Finse) aandelen
Schuitema
Seagull
Sequana Medical
Shurgard
Siemens Gamesa
Sif Holding
Signify
Simac
Sioen Industries
Sipef
Sligro Food Group
SMA Solar technology
Smartphoto Group
Smit Internationale
Snowworld
SNS Fundcoach Beleggingsfondsen Competitie
SNS Reaal
SNS Small & Midcap Competitie
Sofina
Softimat
Solocal Group
Solvac
Solvay
Sopheon
Spadel
Sparen voor later
Spectra7 Microsystems
Spotify
Spyker N.V.
Stellantis
Stellantis
Stern
Stork
Sucraf A en B
Sunrun
Super de Boer
SVK (Scheerders van Kerchove)
Syensqo
Systeem Trading
Taiwan Semiconductor Manufacturing Company (TSMC)
Technicolor
Tele Atlas
Telegraaf Media
Telenet Groep Holding
Tencent Holdings Ltd
Tesla Motors Inc.
Tessenderlo Group
Tetragon Financial Group
Teva Pharmaceutical Industries
Texaf
Theon International
TherapeuticsMD
Thunderbird Resorts
TIE
Tigenix
Tikkurila
TINC
TITAN CEMENT INTERNATIONAL
TKH Group
TMC
TNT Express
TomTom
Transocean
Trigano
Tubize
Turbo's
Twilio
UCB
Umicore
Unibail-Rodamco
Unifiedpost
Unilever
Unilever
uniQure
Unit 4 Agresso
Univar
Universal Music Group
USG People
Vallourec
Value8
Value8 Cum Pref
Van de Velde
Van Lanschot
Vastned
Vastned Retail Belgium
Vedior
VendexKBB
VEON
Vermogensbeheer
Versatel
VESTAS WIND SYSTEMS
VGP
Via Net.Works
Viohalco
Vivendi
Vivoryon Therapeutics
VNU
VolkerWessels
Volkswagen
Volta Finance
Vonovia
Vopak
Warehouses
Wave Life Sciences Ltd
Wavin
WDP
Wegener
Weibo Corp
Wereldhave
Wereldhave Belgium
Wessanen
What's Cooking
Wolters Kluwer
X-FAB
Xebec
Xeikon
Xior
Yatra Capital Limited
Zalando
Zenitel
Zénobe Gramme
Ziggo
Zilver - Silver World Spot (USD)